Connect with us

Technology

Bioprocess Technology Market to Reach USD 134.06 Billion by 2035 – Credence Research

Published

on

LONDON, Oct. 15, 2026 /PRNewswire/ — The “Bioprocess Technology Market – Growth, Share, Opportunities & Competitive Analysis, 2025–2035” report has been added to the Credence Research Inc. market intelligence offering.

The global bioprocess technology market was valued at USD 55.63 billion in 2025 and is estimated at USD 60.75 billion in 2026. Revenue is projected to reach USD 134.06 billion by 2035, representing a compound annual growth rate (CAGR) of 9.19% over the 2025–2035 market-value interval. North America held the largest regional share at 40.0% in 2025, while Asia Pacific is expected to record the fastest growth at 10.38% annually. These revenue forecasts and market shares are Credence Research estimates.

Key Takeaways

The market increases from USD 55.63 billion in 2025 to USD 134.06 billion in 2035 at a stated 9.19% CAGR.North America contributed 40.0% of global 2025 value; Asia Pacific has the highest modeled regional growth rate at 10.38%.Consumables and accessories represented 62.0% of product revenue in 2025.Downstream processing represented 54.0% of process revenue in 2025.Fed-batch technology represented 58.0% of technology revenue in 2025.

Scope & Segmentation – Bioprocess Technology Market

Production equipment, consumables and process technology used to culture cells and purify biologic drug substances, including bioreactors, media, filters, chromatography systems, resins, membranes and analytical instruments. Finished biologic sales, fill-finish equipment and contract manufacturing service revenue are excluded to avoid conflating tools with their end products.

By product: Instruments; Consumables and accessories.By process type: Upstream processing; Downstream processing.By technology: Batch; Fed-batch; Continuous processing.By application: Monoclonal antibodies; Recombinant proteins; Cell and gene therapy products; Antibiotics; Others.By geography: North America; Europe; Asia Pacific; Latin America; Middle East and Africa.

Download sample and detailed segmentation – https://www.credenceresearch.com/report/bioprocess-technology-market 

Why This Report Matters

Maps the commercial drivers of this market without treating forecasts as verified transaction totals.Separates leading applications and products from the regional opportunities and access constraints that affect revenue.Assesses supplier competition, recent regulatory or product developments and likely implications for business planning.

Market Overview

Bioprocess equipment and consumables are critical inputs for making antibodies, vaccines, recombinant proteins and advanced therapies. Unlike the revenue of finished biological medicines, this market measures instruments and materials purchased to manufacture them.

Plant builders invest in bioreactors and purification systems when new capacity comes online, while validated commercial facilities buy media, bags, membranes, resins and reagents repeatedly. Product mix is therefore unusually sensitive to capacity utilization and whether a manufacturer operates stainless steel or single-use systems.

Market Insights

Consumables and accessories represent 62.0% of product value, creating recurring revenue after instruments have been installed.Downstream processing accounts for 54.0% of process revenue because purification and filtration have high cost per batch.Fed-batch remains dominant with 58.0% of technology value; continuous processing is the fastest-growing technology category at a modeled 12.56% CAGR.

Key Attributes

Attribute

Details

Market size, 2025

USD 55.63 billion

Market size, 2035

USD 134.06 billion

CAGR, 2025–2035

9.19 %

Base year

2025

Forecast

2026–2035

Historical reference

2018–2025

Largest regional share

North America (40.0%, 2025)

Fastest-growing region

Asia Pacific (10.38% modeled CAGR)

Revenue units

USD billion at manufacturer or applicable supplier sales level

Segmentation

Product, Process type, Technology, Application, region

Market Segmentation

By product

Instruments; Consumables and accessories

By process type

Upstream processing; Downstream processing

By technology

Batch; Fed-batch; Continuous processing

By application

Monoclonal antibodies; Recombinant proteins; Cell and gene therapy products; Antibiotics; Others

Market Drivers

Growing commercial biologic capacity

Biopharmaceutical companies and contract development and manufacturing organizations are expanding capacity for antibody and cell therapy pipelines. The commissioning of additional sites requires upfront investment in bioreactors, filtration and process monitoring, while each subsequent batch consumes materials that deliver recurring revenue for suppliers.

Shift toward intensification and single-use workflows

Single-use bioreactors shorten turnaround between products and reduce cleaning validation requirements. Intensified perfusion and connected purification can raise output per unit of capacity, but changes to commercial processes require regulatory comparability evidence. Manufacturers often adopt these tools most readily in new plants rather than retrofit fully validated facilities.

Market Trends and Opportunities

Suppliers increasingly offer complete upstream and downstream product ranges. In September 2025, Thermo Fisher completed its approximately USD 4 billion acquisition of Solventum’s filtration and purification business, adding membranes and related technologies.

Process analytical technology, including inline sensors and automated control, may reduce deviation risk and support more efficient batch release. Regulatory incentives can help, although equipment qualification and implementation remain facility-specific.

Regional Analysis

Credence Research estimates the following 2025 revenue shares. All five regional figures are proprietary research-model allocations rather than independently audited sales totals.

North America | 40.0% share in 2025

Established biologics capacity and broad pipelines support recurring demand for resins, media and filters. U.S. manufacturers are also evaluating advanced manufacturing designation and process intensification.

Europe | 29.0% share in 2025

Biologics manufacturing hubs in Switzerland, Germany, Ireland and Denmark support equipment replacement and specialized upstream and downstream consumables.

Asia Pacific | 23.0% share in 2025

New CDMO plants and biosimilar capacity in South Korea, China, India and Singapore are driving 10.38% annual modeled growth.

Latin America | 4.5% share in 2025

Vaccine, insulin and biosimilar localization programs expand demand for fermentation, filtration and purification tools, especially in Brazil and Mexico.

Middle East and Africa | 3.5% share in 2025

Local biomanufacturing initiatives create opportunities for modular systems, while workforce and validation constraints limit implementation scale.

Market Challenges

A change in resins, membrane materials or equipment may require new process validation and regulatory submissions. For established products, switching can be uneconomical despite the potential for productivity gains.

Capital-intensive instrument orders can fluctuate with biotechnology funding and construction schedules. Specialized operators and quality staff remain scarce, while single-use plastic waste and supply dependence create operational constraints.

Future Outlook

Bioprocess spending is expected to grow fastest where new CDMO capacity meets expanding portfolios of complex biologics. Consumables should preserve repeat sales even if capital project timing varies.

The strongest technology providers will combine dependable supply, process documentation, training, high-value purification tools and automation support.

Competitive Landscape

Competition among full-line suppliers centers on the breadth of validated components and integrated production workflows. Thermo Fisher, Danaher, Sartorius and Merck KGaA supply combinations of cell culture, filtration and purification products.

Eppendorf, Bio-Rad, Agilent and specialized equipment firms compete in process development, analytics and particular hardware categories. Lonza and Roche are major manufacturing operators and equipment customers, rather than primarily direct competitors as process-tool vendors.

Key Players

Thermo Fisher Scientific; Danaher (Cytiva and Pall); Sartorius; Merck KGaAEppendorf; Bio-Rad Laboratories; Agilent Technologies; GetingeAdvanced Instruments

Recent Industry Developments

Dec. 31, 2024: The FDA finalized its Advanced Manufacturing Technologies Designation Program guidance, which describes an early-engagement pathway for qualifying technologies.  Sept. 2, 2025: Thermo Fisher completed its acquisition of Solventum’s purification and filtration business for approximately USD 4.0 billion in cash. 

Report Coverage

Quantitative market size and CAGR through 2035, with base-year segmentation, regional shares and technology or product trends.Demand drivers, competition, market restraints, policy and reimbursement where relevant, and primary supplier dynamics.Recent industry events supported by original regulator or company sources.Credence Research forecasts, shares and segment models are proprietary estimates; they are not independently audited figures.

Read the complete report and request a customized study: https://www.credenceresearch.com/report/bioprocess-technology-market 

Related Reports

Upstream Bioprocessing MarketSingle-Use Upstream Bioprocessing Technology MarketSingle-Use Downstream Bioprocessing MarketSingle-Use Bio-Processing Systems MarketBioreactors Market

About Us

Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. The company provides quantitative industry research, competitive analysis and strategic advisory services to organizations assessing market opportunities and investment decisions. Its reports combine primary and secondary research to evaluate market size, segmentation, growth drivers, emerging technologies and regional commercial conditions.

Credence Research serves business leaders, investors, governments, nonprofits and other stakeholders across industries, with research deliverables designed to inform product planning, market entry and competitive positioning.

Contact Us

Credence Research Inc.
Tower C-1105, S 25, Akash Tower
Vishal Nagar, Pimple Nilakh, Haveli
Pune – 411027, India
Europe Phone: +44 7453 598 606
US Phone: +1 6282 627 656
Email: sales@credenceresearch.com 

Website: www.credenceresearch.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/bioprocess-technology-market-to-reach-usd-134-06-billion-by-2035—credence-research-302910458.html

Continue Reading

Technology

ASSA ABLOY sells PKI business unit to Vista Equity Partners

Published

on

By

STOCKHOLM, Oct. 16, 2026 /PRNewswire/ — ASSA ABLOY has signed an agreement to sell HID’s PKI business unit to Vista Equity Partners (“Vista”).

The PKI business unit (Public Key Infrastructure) provides digital trust, identity, authentication, encryption, and certificate management solutions. The business unit includes PKI SaaS – IdenTrust and HydrantID – credential management, and ZeroSSL.

“I find it very satisfying that with Vista, the PKI business unit and its employees and customers gain a committed long-term investor, creating new opportunities for the future and I wish them every success,” says Nico Delvaux, President and CEO of ASSA ABLOY.

“Our PKI team has built a strong business with a strong customer base, and Vista has the expertise to take it forward as the market evolves,” says Björn Lidefelt, EVP and Head of HID. “We are pleased with this outcome for our customers, our employees, and for HID.”

The divested business had sales in 2025 of MUSD 58 (approx. MSEK 570) with a strong operating margin.

The divestiture is subject to customary closing conditions and is expected to close during the fourth quarter of 2026.

For more information, please contact: 
Nico Delvaux, President and CEO, tel. no: +46 8 506 485 82
Erik Pieder, CFO and Executive Vice President, tel. no: +46 8 506 485 72
Björn Tibell, Head of Investor Relations, tel. no: +46 70 275 67 68, e-mail: bjorn.tibell@assaabloy.com

About ASSA ABLOY
ASSA ABLOY is the global leader in access solutions. Every day we help people feel safe, secure and experience a more open world. We operate worldwide with 64,000 employees and sales of SEK 152 billion, with leading positions in areas such as efficient door openings, trusted identities and entrance automation. Our innovations enable safe, secure and convenient access to physical and digital places.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/assa-abloy/r/assa-abloy-sells-pki-business-unit-to-vista-equity-partners,c4410007

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/assa-abloy-sells-pki-business-unit-to-vista-equity-partners-302911635.html

Continue Reading

Technology

QBTS Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against D-Wave Quantum Inc.

Published

on

By

SAN DIEGO, Oct. 16, 2026 /PRNewswire/ — Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons who purchased or otherwise acquired D-Wave (NYSE: QBTS) securities between February 26, 2026 and August 25, 2026, inclusive (the “Class Period”). D-Wave is a company engaged in quantum computing.

The complaint alleges that D-Wave overstated its business and financial prospects.

The complaint alleges that D-Wave overstated its business and financial prospects.

Investors who purchased D-Wave Quantum Inc. securities during the Class Period and suffered significant losses should contact Robbins LLP before December 15, 2026 for information about the lawsuit.

Why Was D-Wave Sued?

According to the complaint, during the Class Period, defendants failed to disclose that:

(i) defendants materially overstated D-Wave’s business and financial prospects;
(ii) the foregoing was reasonably likely to negatively impact the Company’s business and reputation; and
(iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Why Did D-Wave Stock Drop?

According to the complaint, the truth started to emerge on August 6, 2026, when D-Wave announced its financial results for the second quarter of 2026. Among other things, D-Wave reported revenue of just $3.08 million, compared to $3.1 million for the same period in the prior year, falling short of analyst expectations ranging from $4.03 million to $4.08 million. On this news, D-Wave’s stock price declined $1.99 per share, or 9.28%, to close at $19.41 per share on August 6, 2026.

Then, on August 25, 2026, D-Wave issued a press release “announc[ing] that John Markovich is retiring and thus resigning from his position as Chief Financial Officer effective September 2, 2026.” On this news, D-Wave’s stock price fell $1.84 per share, or 9.51%, closing at $17.51 per share on August 26, 2026.

What Can D-Wave Shareholders Do Now?

Investors who purchased D-Wave Quantum Inc. securities during the Class Period may be eligible to serve as lead plaintiff. The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to seek appointment as lead plaintiff should contact Robbins LLP before the December 15, 2026 deadline for information about the appointment process.

Shareholders do not need to serve as lead plaintiff to share in any potential recovery. Investors who do not seek appointment may remain absent class members.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis, with no upfront or out-of-pocket fees or expenses.

Contact Robbins LLP

Investors seeking additional information about the D-Wave Quantum Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history. 

“Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently,” said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against D-Wave Quantum Inc. settles, or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View original content to download multimedia:https://www.prnewswire.com/news-releases/qbts-stockholder-notice-robbins-llp-reminds-investors-of-the-class-action-lawsuit-against-d-wave-quantum-inc-302911530.html

SOURCE Robbins LLP

Continue Reading

Technology

BUUU Group Limited Announces 10-for-1 Forward Share Split

Published

on

By

SINGAPORE, Oct. 16, 2026 /PRNewswire/ — BUUU Group Limited (Nasdaq: BUUU) (“BUUU” or the “Company”) today announced that its board of directors has approved a ten-for-one (10-for-1) forward split of the Company’s ordinary shares, to be effected by subdividing each of the Company’s issued and unissued Class A ordinary shares and Class B ordinary shares into ten shares of the same class (the “Share Subdivision”). The Share Subdivision is intended to make the Company’s Class A ordinary shares more accessible to a broader base of investors and to enhance their trading liquidity. Subject to processing by Nasdaq, the Class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on October 26, 2026, under the Company’s existing symbol “BUUU.”

The Share Subdivision follows BUUU’s completion on September 15, 2026 of its acquisition of a 60% equity interest in Brightray Science Inc., through which the Company has established industrialized AI data center delivery as its core growth business.

Details of the Share Subdivision

Key date. The Class A ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on October 26, 2026.

Ratio and mechanics. As a result of the Share Subdivision, each issued Class A ordinary share and each issued Class B ordinary share will be automatically subdivided into ten shares of the same class. As a result, each shareholder will hold ten shares of the relevant class for every share held immediately before the Share Subdivision (equivalent to nine additional shares for each share held). The Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “BUUU.” The new CUSIP number of the Class A ordinary shares following the Share Subdivision will be G1739L110.

Authorized and outstanding shares. In connection with the Share Subdivision, the maximum number of shares the Company is authorized to issue will increase proportionately from 500,000,000 shares of no par value, divided into 250,000,000 Class A ordinary shares and 250,000,000 Class B ordinary shares, to 5,000,000,000 shares of no par value, divided into 2,500,000,000 Class A ordinary shares and 2,500,000,000 Class B ordinary shares.

Rights and ownership unchanged. The rights and restrictions attaching to each class of shares will remain unchanged, including the voting rights of one vote per Class A ordinary share and twenty votes per Class B ordinary share, and all shares of each class resulting from the Share Subdivision will rank pari passu in all respects with each other. The Share Subdivision will not change any shareholder’s percentage ownership interest or voting power in the Company. No fractional shares will result from the Share Subdivision.

No action required unless you hold physical certificates. No action is required by shareholders. Shareholders who hold Class A ordinary shares through a bank, broker or other nominee will have their positions automatically adjusted to reflect the Share Subdivision, subject to their nominee’s particular processes. The Company’s transfer agent, VStock Transfer, LLC (“VStock”), will update the holdings of registered shareholders in book-entry form. Registered shareholders holding share certificates will be asked to deliver a letter of transmittal to VStock to surrender their certificates to VStock in exchange for the right to receive post-Share Subdivision ordinary shares in electronic, book-entry form.

Outstanding securities. Proportionate adjustments will be made, to the extent provided by their respective terms, to the number of Class A ordinary shares issuable upon the exercise, conversion or settlement of, and to the exercise price or other per-share terms of, the Company’s outstanding warrants and other securities exercisable for, convertible into or settleable in Class A ordinary shares.

Approval. The Share Subdivision was approved by the Company’s board of directors on September 28, 2026.

The Company will furnish a copy of this press release to the U.S. Securities and Exchange Commission (the “SEC”) on Form 6-K.

About BUUU Group Limited

BUUU Group Limited (Nasdaq: BUUU) has established industrialized AI data center delivery as its core growth business, operated through Brightray Science Inc., in which BUUU acquired a controlling interest in September 2026. BUUU also provides meetings, incentives, conferences and exhibitions (MICE) solutions, including event management and stage production, for public institutions, agencies, real estate companies and established brands.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “would,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” and similar expressions. Forward-looking statements include statements regarding the expected timing and effectiveness of the Share Subdivision, including the date on which the Class A ordinary shares are expected to begin trading on a split-adjusted basis; the intended effects of the Share Subdivision, including on the accessibility and trading liquidity of the Class A ordinary shares; and the Company’s business strategy and prospects. Such statements are based on current expectations and assumptions and involve risks and uncertainties, many of which are beyond the control of BUUU, that could cause actual results to differ materially from those contained in the forward-looking statements. These risks and uncertainties include, but are not limited to: delays in, or the failure to complete, the steps required to implement the Share Subdivision, including registration of the amendment to the Company’s memorandum and articles of association in the British Virgin Islands and processing by Nasdaq, The Depository Trust Company, the Company’s transfer agent and brokers; the possibility that the Share Subdivision does not achieve its intended effects, including any improvement in trading liquidity or broadening of the Company’s investor base; the market price and trading volume of the Class A ordinary shares following the Share Subdivision, which may not adjust proportionately to the Share Subdivision, and the possibility of increased volatility; the effect of a lower per-share trading price on the Company’s continued compliance with Nasdaq listing requirements, including the minimum bid price requirement; the integration of Brightray into BUUU; competition in the data center industry; demand for AI computing infrastructure; changes in laws and regulations affecting the data center and AI computing industries, including trade and export control measures; and other risks described in BUUU’s filings with the SEC, including its most recent annual report on Form 20-F. Forward-looking statements speak only as of the date of this press release, and BUUU undertakes no obligation to update any forward-looking statement, except as required by applicable law.

 

View original content:https://www.prnewswire.com/news-releases/buuu-group-limited-announces-10-for-1-forward-share-split-302911448.html

SOURCE BUUU Group Limited

Continue Reading

Trending